SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
Sarepta Therapeutics Inc. (SRPT) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Sarepta Therapeutics, Inc. (SRPT) has launched a first in human trial called INSIGHTT to test SRP-1005 in people with Huntington’s disease. The goal is to see how safe the drug is, how the body handles it, and whether it shows early signs of helping this severe and still poorly treated brain disorder.
The study is testing SRP-1005, a drug given by under the skin injection, against placebo. The aim is to find a safe dose range that could move into larger trials and, if successful, add a new growth pillar beyond Sarepta’s core genetic muscle disease portfolio.
The trial is interventional and randomized, meaning participants are assigned by chance to drug or placebo in parallel groups. It is triple blind, so patients, care staff, and investigators do not know who gets SRP-1005, and the main goal is treatment focused rather than diagnosis or prevention.
The study was first submitted on April 10, 2026, marking the formal start of the clinical plan. The latest update on June 3, 2026 confirms the recruiting status and signals that design and site work are active rather than static on the registry.
As a Phase 1 trial, this update is more about long term option value than near term revenue for SRPT. If early safety and signals look good, investors may start to price in a broader neurology pipeline, though they will also weigh competition from other Huntington’s disease players and the long, risky road to approval.
The INSIGHTT study of SRP-1005 in Huntington’s disease is currently ongoing and updated, with full details available on the ClinicalTrials portal.
To learn more about SRPT’s potential, visit the Sarepta Therapeutics Inc. drug pipeline page.
